Dapagliflozin (5mg), Vildagliptin SR (50mg) . . . . . .

Type 2 Diabetes Mellitus (T2DM) has emerged as one of the most common lifestyle-related disorders in India, affecting millions of adults across different age groups. Characterised by insulin resistance, impaired insulin secretion, and persistent hyperglycaemia, uncontrolled diabetes can gradually lead to serious complications such as heart disease, kidney damage, nerve damage, and vision problems. Effective and sustained glycaemic control is therefore essential to prevent long-term complications and maintain quality of life.

DAPA VILDA 50/5 is a scientifically formulated combination of dapagliflozin and vildagliptin, designed to provide comprehensive blood sugar control through two complementary mechanisms of action. This dual therapy targets multiple pathways involved in glucose regulation, making it highly effective for patients who do not achieve adequate control with single-drug therapy.

Dapagliflozin belongs to the class of SGLT2 inhibitors, which lower blood glucose by promoting glucose excretion through urine, while Vildagliptin SR is a DPP-4 inhibitor that enhances insulin secretion and suppresses glucagon release in a glucose-dependent manner. Together, they offer balanced, sustained, and safe glycaemic control with additional metabolic benefits.

Dapagliflozin and Vildagliptin Tablet of Uses

 Dapagliflozin and vildagliptin tablet uses is primarily indicated for the management of Type 2 Diabetes Mellitus in adults. Its uses include:

1. Management of Type 2 Diabetes Mellitus

• Helps control fasting and postprandial blood glucose levels

• Suitable for patients inadequately controlled on diet, exercise, or monotherapy

2. Combination Therapy for Better Glycaemic Control

• Ideal for patients requiring dual-action treatment

• Addresses both insulin resistance and insulin secretion defects

3. Add-on Therapy with Lifestyle Modification

• Used alongside dietary control and regular physical activity

• Enhances overall diabetes management outcomes

4. Support in Long-Term Diabetes Control

• Helps maintain stable HbA1c levels

• Reduces glycaemic variability over time

5. Metabolic and Cardiovascular Support

• Dapagliflozin supports weight management and blood pressure control

• May contribute to improved cardiovascular and renal outcomes under medical supervision

Dapagliflozin and Vildagliptin Tablet of Benefits

1. Dual Mechanism for Superior Glycaemic Control

• Dapagliflozin reduces glucose reabsorption in kidneys

• Vildagliptin SR improves insulin response and lowers glucagon secretion

2. Sustained Blood Sugar Regulation

• Extended-release Vildagliptin ensures 24-hour glucose control

• Reduces fluctuations between meals and overnight

3. Low Risk of Hypoglycaemia

• Acts in a glucose-dependent manner

• Safer profile when used as prescribed, especially compared to sulfonylureas

4. Supports Weight Neutrality or Weight Reduction

• Dapagliflozin promotes calorie loss through urine

• Beneficial for overweight or obese diabetic patients

5. Improves Patient Compliance

• Single-tablet combination reduces pill burden

• Simplifies treatment regimen for long-term adherence

6. Renal and Cardiometabolic Benefits

• SGLT2 inhibition helps reduce renal glucose load

• Supports heart and kidney health in suitable patients

7. Well-Tolerated and Clinically Trusted

• Backed by extensive clinical research

• Widely recommended by diabetologists as combination therapy

Dapagliflozin and Vildagliptin Tablet of Dosage and Administration

Recommended Dosage

• One tablet of DAPA VILDA 50/5 once daily, or as directed by a physician

• Dose may be adjusted based on glycaemic response and patient profile

Method of Intake

• Swallow the tablet whole with water

• Preferably taken at the same time each day

• Can be taken with or without food, as advised

Duration of Treatment

• Intended for long-term use in chronic diabetes management

• Regular monitoring of blood glucose and HbA1c is recommended

Important Usage Tips

• Do not crush or chew the tablet

• Maintain adequate hydration while on therapy

• Continue prescribed diet and exercise plan

Dapagliflozin and Vildagliptin Tablet of Side Effects 

Most patients tolerate vildagliptin and dapagliflozin  well. However, some individuals may experience mild to moderate side effects.

Common Side Effects

• Increased urination

• Mild headache or dizziness

• Nasopharyngitis or upper respiratory tract infection

• Gastrointestinal discomfort

Less Common Side Effects

• Genital or urinary tract infections

• Mild hypoglycaemia (especially when combined with other antidiabetic drugs)

• Fatigue

Rare but Serious Side Effects

• Dehydration or low blood pressure

• Pancreatitis (rare)

• Allergic reactions such as rash or swelling

If any unusual or persistent symptoms occur, medical consultation is advised immediately.

Precautions and Warnings

General Precautions

• Use strictly under medical supervision

• Do not exceed the prescribed dose

Kidney and Liver Function

• Regular monitoring of renal and hepatic parameters is essential

• Not recommended in severe renal impairment unless advised by a specialist

Risk of Infections

• Maintain good personal hygiene to reduce the risk of urinary and genital infections

Hypoglycaemia Risk

• Risk increases if combined with insulin or sulfonylureas

• Monitor blood glucose regularly

Pregnancy and Breastfeeding

• Not recommended unless clearly advised by a healthcare professional

Drug Interactions

• Inform your doctor about all medications and supplements you are taking

Lifestyle Advice

• Continue balanced diet, regular exercise, and weight management

• Stay well hydrated during treatment

Conclusion

DAPA VILDA 50/5, combining  vildagliptin and dapagliflozin tablets, represents a modern, effective, and patient-friendly approach to the management of Type 2 Diabetes Mellitus. By addressing multiple mechanisms of glucose regulation, it provides consistent blood sugar control, improved metabolic outcomes, and enhanced patient compliance.

With its dual-action benefits, low risk of hypoglycaemia, and added cardiometabolic advantages, DAPA VILDA 50/5 is a valuable option for patients seeking long-term diabetes control. When used alongside lifestyle modifications and regular medical monitoring, it helps patients move toward better glycaemic stability, reduced complications, and improved quality of life.

Frequently Asked Questions (F&Q)

Who should take DAPA VILDA 50/5?

It is prescribed for adults with Type 2 Diabetes Mellitus who need better glycaemic control with combination therapy.

Can it be used as first-line treatment?

It may be prescribed when monotherapy is insufficient. The decision depends on clinical judgement and patient needs.

Does it cause weight gain?

No. Dapagliflozin may support weight reduction or weight neutrality.

Is it safe for long-term use?

Yes, when taken under regular medical supervision with appropriate monitoring.

Can elderly patients take this medicine?

Yes, but dose adjustment and renal function monitoring may be required.